DK0434450T3 - Terapeutiske nucleosider - Google Patents

Terapeutiske nucleosider

Info

Publication number
DK0434450T3
DK0434450T3 DK90314089T DK90314089T DK0434450T3 DK 0434450 T3 DK0434450 T3 DK 0434450T3 DK 90314089 T DK90314089 T DK 90314089T DK 90314089 T DK90314089 T DK 90314089T DK 0434450 T3 DK0434450 T3 DK 0434450T3
Authority
DK
Denmark
Prior art keywords
therapeutic nucleosides
nucleosides
therapeutic
Prior art date
Application number
DK90314089T
Other languages
Danish (da)
English (en)
Inventor
Susan Mary Daluge
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/455,201 external-priority patent/US5034394A/en
Application filed by Wellcome Found filed Critical Wellcome Found
Application granted granted Critical
Publication of DK0434450T3 publication Critical patent/DK0434450T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK90314089T 1989-12-22 1990-12-21 Terapeutiske nucleosider DK0434450T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/455,201 US5034394A (en) 1988-06-27 1989-12-22 Therapeutic nucleosides

Publications (1)

Publication Number Publication Date
DK0434450T3 true DK0434450T3 (da) 2000-01-31

Family

ID=23807819

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90314089T DK0434450T3 (da) 1989-12-22 1990-12-21 Terapeutiske nucleosider

Country Status (30)

Country Link
EP (3) EP0921121A1 (el)
JP (2) JPH11158160A (el)
CN (1) CN1028106C (el)
AP (1) AP196A (el)
AT (1) ATE181917T1 (el)
AU (1) AU633672B2 (el)
CA (1) CA2033044C (el)
CY (1) CY2145B1 (el)
CZ (1) CZ283481B6 (el)
DE (2) DE19975058I1 (el)
DK (1) DK0434450T3 (el)
ES (1) ES2133138T3 (el)
FI (2) FI106461B (el)
GR (1) GR3031100T3 (el)
HK (1) HK1009600A1 (el)
HU (3) HU219454B (el)
IE (3) IE904652A1 (el)
IL (1) IL96748A (el)
LU (1) LU90426I2 (el)
MX (1) MX9203215A (el)
MY (1) MY104575A (el)
NL (1) NL990028I2 (el)
NZ (1) NZ236593A (el)
PL (1) PL167097B1 (el)
PT (1) PT96321B (el)
RU (2) RU2068849C1 (el)
SG (1) SG49685A1 (el)
SK (2) SK658390A3 (el)
TW (2) TW473466B (el)
ZA (1) ZA9010365B (el)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2793825B2 (ja) * 1988-01-20 1998-09-03 リージヤンツ・オブ・ザ・ユニバーシテイ・オブ・ミネソタ ジデオキシジデヒドロ炭素環式ヌクレオシド
CA2001401A1 (en) * 1988-10-25 1990-04-25 Claude Piantadosi Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
GB9108376D0 (en) * 1991-04-19 1991-06-05 Enzymatix Ltd Cyclopentenes
GB9204015D0 (en) * 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
GB9205071D0 (en) * 1992-03-09 1992-04-22 Wellcome Found Therapeutic nucleosides
ATE226437T1 (de) * 1993-06-10 2002-11-15 Univ Wake Forest (phospho)lipide zum bekämpfen einer hepatitis b- infektion
GB9402161D0 (en) * 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
GB9417249D0 (en) * 1994-08-26 1994-10-19 Wellcome Found A novel salt
EP1852121A3 (en) 1994-08-29 2007-11-21 Wake Forest University Lipid analogs for treating viral infections
US7135584B2 (en) 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
US5977061A (en) * 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
GB9600142D0 (en) * 1996-01-05 1996-03-06 Wellcome Found Chemical compounds
ID19490A (id) 1996-06-25 1998-07-16 Glaxo Group Ltd Kombinasi-kombinasi antiviral
PL330791A1 (en) * 1996-06-25 1999-06-07 Glaxo Group Ltd Vx478, zidovudin, ftc and/or 3tc containing combinations for use in treating hiv infections
SK285228B6 (sk) * 1997-05-13 2006-09-07 Lonza Ag Spôsob výroby racemického alebo opticky aktívnehoderivátu 4-(hydroxymetyl)-2-cyklopenténu a racemicky N-butyryl-1-amino-4- (hydroxymetyl)-2-cyklopentén
AU769660B2 (en) * 1997-05-17 2004-01-29 Glaxo Group Limited Carbocyclic nucleoside hemisulfate and its use in treating viral infections
GB9709945D0 (en) * 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
GB9721780D0 (en) * 1997-10-14 1997-12-10 Glaxo Group Ltd Process for the synthesis of chloropurine intermediates
WO1999021861A1 (en) * 1997-10-24 1999-05-06 Glaxo Group Limited Process for preparing a chiral nucleoside analogue
JP2001522850A (ja) * 1997-11-12 2001-11-20 グラクソ グループ リミテッド キラルヌクレオシド類似体の製造法
SK284594B6 (sk) * 1997-11-27 2005-07-01 Lonza Ag Spôsob výroby derivátov aminoalkoholov a ich soli
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
GB9802472D0 (en) * 1998-02-06 1998-04-01 Glaxo Group Ltd Pharmaceutical compositions
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
GB9821058D0 (en) * 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
US6433170B1 (en) 1998-10-30 2002-08-13 Lonza Group Method for producing 4-[2',5'-diamino-6'-halopyrimidine-4'-yl)amino]- cyclopent-2-enylmethanols
CA2348374C (en) * 1998-10-30 2009-04-07 Lonza Ag Method for producing 4- [(2',5'- diamino-6'- halopyrimidine- 4'-yl)amino]- cyclopent- 2-enylmethanols
GB9903091D0 (en) 1999-02-12 1999-03-31 Glaxo Group Ltd Therapeutic nucleoside compound
US7026469B2 (en) 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
WO2001042255A1 (en) * 1999-12-10 2001-06-14 Glaxo Group Limited (1R,CIS)-4-(4-AMINO-7H-PYRROLO'2,3-I(D) ! PYRIMIDINE-7-YL)-2-CYCLOPENTENE-1-METHANOL DERIVATIVES AS ANTIVIRAL
PE20010915A1 (es) * 1999-12-10 2001-09-29 Glaxo Group Ltd Analogos de (1s, cis)-4-(2-amino-9h-purin-9-il)-2-ciclopenten-1-metanol para uso en el tratamiento de infecciones virales
DE10042655A1 (de) * 2000-08-31 2002-03-14 Aventis Pharma Gmbh Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion
US7309696B2 (en) 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
IL159494A0 (en) 2001-06-29 2004-06-01 Acad Of Science Czech Republic 6-2'-(phosphonomethoxy) alkoxy pyrimidine derivatives having antiviral activity
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
AU2002323034A1 (en) * 2001-08-21 2003-03-10 Glaxo Group Limited Method of screening for drug hypersensitivity reaction
US7550261B2 (en) 2001-08-21 2009-06-23 Smithkline Beecham Corporation Method of screening for drug hypersensitivity reaction
JP4714413B2 (ja) 2001-08-31 2011-06-29 トムソン ライセンシング オーディオビジュアルストリームのためのシーケンスカウンタ
US6780635B2 (en) 2001-12-27 2004-08-24 Council Of Scientific And Industrial Research Process for the preparation of optically active azabicyclo heptanone derivatives
AU2003239088B2 (en) * 2002-06-27 2006-11-02 Medivir Ab Synergistic interaction of abacavir and alovudine
NZ543864A (en) 2003-06-16 2009-10-30 Leuven K U Res & Dev Pyrimidine compounds having phosphonate groups as antiviral nucleotide analogs
GB0320738D0 (en) 2003-09-04 2003-10-08 Glaxo Group Ltd Novel process
EP1857458A1 (en) * 2006-05-05 2007-11-21 SOLMAG S.p.A. Process for the preparation of abacavir
CA2662586A1 (en) * 2006-09-28 2008-04-03 Esteve Quimica, S.A. Process for the preparation of abacavir
EP1905772A1 (en) 2006-09-28 2008-04-02 Esteve Quimica, S.A. Process for the preparation of abacavir
EP1939196A1 (en) * 2006-12-21 2008-07-02 Esteve Quimica, S.A. Process for the preparation of abacavir
PT2159224E (pt) 2007-06-18 2012-10-24 Sunshine Lake Pharma Co Ltd Tiazolil dihidropirimidinas substituídas com bromo-fenilo
EP2085397A1 (en) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
EP2340252B1 (en) 2008-09-09 2015-11-11 AstraZeneca AB A process for preparing [1s- ]1-alpha, 2-alpha, 3-beta (1s*, 2r*) 5-beta] ]-3- [7- [2- (3, 4-dif luorophenyl) -cyclopropylamino]- 5- (propylthio) -3h-1, 2, 3-triazolo [4, 5-d]pyrimidin-3-yl]-5- (2- hydroxyethoxy) cyclopentane-1, 2-diol and to its intermediates
ES2607069T3 (es) * 2012-01-03 2017-03-29 Cellceutix Corporation Nucleósidos carbocíclicos y su uso farmacéutico y composiciones
WO2014133085A1 (ja) 2013-02-27 2014-09-04 国立大学法人京都大学 がんの予防または治療用医薬組成物
EP3052499B1 (en) 2013-10-03 2017-11-15 Lupin Limited Crystalline abacavir hydrochloride monohydrate and process for its preparation
CN104558035B (zh) * 2013-10-22 2017-12-19 连云港恒运药业有限公司 一种替诺福韦前药的纯化方法
CN104788451A (zh) * 2014-01-21 2015-07-22 浙江九洲药业股份有限公司 一种阿巴卡韦的制备方法
CN109239253B (zh) * 2018-09-21 2021-07-09 江苏威奇达药业有限公司 一种阿巴卡韦的杂质的高效液相检测方法
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU1787160C (ru) * 1986-12-24 1993-01-07 Эли Лилли Энд Компани Способ получени иммуноглобулинового конъюгата
JP2793825B2 (ja) * 1988-01-20 1998-09-03 リージヤンツ・オブ・ザ・ユニバーシテイ・オブ・ミネソタ ジデオキシジデヒドロ炭素環式ヌクレオシド
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
EP0366385B1 (en) * 1988-10-24 1993-06-09 The Wellcome Foundation Limited Guanine derivatives having antiviral activity and their pharmaceutically acceptable salts
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
US4939252A (en) * 1989-04-20 1990-07-03 Hoffmann-La Roche Inc. Novel intermediates for the preparation of Carbovir

Also Published As

Publication number Publication date
IE990825A1 (en) 2000-12-13
CN1028106C (zh) 1995-04-05
IE990826A1 (en) 2000-12-13
CZ658390A3 (en) 1997-11-12
CZ283481B6 (cs) 1998-04-15
NZ236593A (en) 1994-01-26
FI20001175A (fi) 2000-05-16
IE904652A1 (en) 1991-07-17
PL288403A1 (en) 1992-06-26
LU90426I2 (fr) 1999-10-06
AP196A (en) 1992-06-30
CY2145B1 (en) 2002-06-21
HU9902543D0 (en) 1999-10-28
ATE181917T1 (de) 1999-07-15
HK1009600A1 (en) 1999-06-04
IL96748A (en) 1995-07-31
CA2033044C (en) 1999-07-13
EP0434450A3 (en) 1992-07-08
HU9008407D0 (en) 1991-07-29
RU2068849C1 (ru) 1996-11-10
FI906367A (fi) 1991-06-23
PT96321B (pt) 1998-06-30
MX9203215A (es) 1992-07-01
JPH11158160A (ja) 1999-06-15
MY104575A (en) 1994-04-30
SK247092A3 (en) 1999-06-11
AU6841990A (en) 1991-06-27
ZA9010365B (en) 1992-08-26
AU633672B2 (en) 1993-02-04
SG49685A1 (en) 1998-06-15
CN1054981A (zh) 1991-10-02
DE69033197D1 (de) 1999-08-12
HU220630B1 (hu) 2002-03-28
HU9902539D0 (en) 1999-10-28
PT96321A (pt) 1991-09-30
TW371660B (en) 1999-10-11
DE19975058I1 (de) 2007-01-25
EP0921114A1 (en) 1999-06-09
SK280216B6 (sk) 1999-10-08
NL990028I1 (nl) 1999-11-01
GR3031100T3 (en) 1999-12-31
SK658390A3 (en) 1999-10-08
HU219454B (hu) 2001-04-28
ES2133138T3 (es) 1999-09-01
JPH11343292A (ja) 1999-12-14
EP0434450A2 (en) 1991-06-26
FI106461B (fi) 2001-02-15
TW473466B (en) 2002-01-21
AP9000234A0 (en) 1991-01-31
CA2033044A1 (en) 1991-06-23
FI906367A0 (fi) 1990-12-21
EP0434450B1 (en) 1999-07-07
PL167097B1 (pl) 1995-07-31
IL96748A0 (en) 1991-09-16
SK280000B6 (sk) 1999-06-11
DE69033197T2 (de) 1999-10-28
NL990028I2 (nl) 2000-02-01
HU220067B (hu) 2001-10-28
RU2091386C1 (ru) 1997-09-27
EP0921121A1 (en) 1999-06-09

Similar Documents

Publication Publication Date Title
DK0434450T3 (da) Terapeutiske nucleosider
ATE138660T1 (de) Therapeutische nukleoside
KR910002326A (ko) 치료용 뉴클레오시드
DK191688A (da) Terapeutiske nucleosider
DK23489A (da) Nucleosidderivater
DK406689A (da) Terapeutiske nucleosider
DK140588A (da) Terapeutisk nucleosider
PT100435A (pt) Nucleosidos terapeuticos
KR900015343U (ko) 안마겸용 때밀이 장치
GB8912972D0 (en) Therapeutic nucleosides
DK725088D0 (da) Terapeutiske nucleosider
KR900016687U (ko) 안마구
NO921776L (no) Nukleosid-derivater
KR910010852U (ko) 안마기
KR900014255U (ko) 안마구
KR900019989U (ko) 지압 완력기
BR6801186U (pt) Sela magalarga
GB8901294D0 (en) Therapeutic nucleosides
GB8922285D0 (en) Therapeutic nucleosides